Core Oncology is a women’s health company committed to the advancement of treatments for early stage breast cancer through innovations in radiation therapy. Women diagnosed with early stage breast cancer most commonly chose Breast Conserving Therapy (BCT) also referred to as lumpectomy for their treatment of choice. Radiation therapy is typically prescribed after BCT as part of the treatment. Core’s mission is to expand the options of how this radiation is delivered in an effort to minimize overall treatment time while improving patient’s quality of life.
Our focus on development of innovative products for the treatment for breast cancer began in 2004 when we partnered with founder of the technique, Dr. Jean-Philippe Pignol, in support of the Phase I/II clinical trials. In 2007 Core began the development of the patent pending Artemend System. This system was specifically developed to facilitate the Breast Microseed Treatment technique.
Core’s proprietary Artemend Breast Microseed Treatment now offers a new option for women requiring post BCT radiation treatment. Through this innovative technology women are able to reduce their treatment time from weeks to a single, one-hour, one-time treatment while reducing radiation exposure to the heart, lungs and chest wall during treatment*. Artemend Breast Microseed Treatment allows women the peace of mind necessary to focus on life after breast cancer in the shortest amount of time.
* - References